Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 1,700 shares, a decline of 34.6% from the July 31st total of 2,600 shares. Based on an average trading volume of 1,700 shares, the short-interest ratio is currently 1.0 days.

Clinuvel Pharmaceuticals Trading Down 0.3 %

Shares of CLVLY stock traded down $0.03 during trading on Friday, hitting $10.30. The company had a trading volume of 4,286 shares, compared to its average volume of 2,831. The stock’s 50-day moving average price is $9.76 and its 200 day moving average price is $9.76. Clinuvel Pharmaceuticals has a one year low of $8.42 and a one year high of $13.45.

Clinuvel Pharmaceuticals Increases Dividend

The business also recently declared a dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a $0.0299 dividend. This is a boost from Clinuvel Pharmaceuticals’s previous dividend of $0.03. The ex-dividend date of this dividend is Monday, September 9th.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).